PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer

The incidence of breast cancer brain metastases has increased in recent years, largely due to improved control of systemic disease with human epidermal growth factor receptor 2 (HER2)-targeted agents and the inability of most of these agents to efficiently cross the blood–blood barrier (BBB) and con...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuro-oncology 2014-03, Vol.117 (1), p.7-13
Hauptverfasser:	Peddi, Parvin F., Hurvitz, Sara A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - therapeutic use Brain Neoplasms - drug therapy Brain Neoplasms - secondary Breast Neoplasms - metabolism Breast Neoplasms - pathology Enzyme Inhibitors - therapeutic use Female Humans Medicine Medicine & Public Health Neurology Oncology Phosphatidylinositol 3-Kinases - antagonists & inhibitors Receptor, ErbB-2 - metabolism Signal Transduction - drug effects Topic Review TOR Serine-Threonine Kinases - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!